Immuno Oncology Market by 2022- A Global Forecast

World’s one of the biggest and liable market research resource, Research and Markets recently published Immuno-Oncology Market, By Type and By Application- Global Forecast 2022.

Presently, Immuno oncology market has experienced a substantial number of improvements. The level of competition between the companies is accelerating. The biotechnology and pharmaceutical firms are attempting to obtain first mover benefits by introducing new and most effective therapies. This therapy is predicted to…

CDSCO Issues Alert on Using Avastin for AMD

Indian regulatory authority Central Drugs Standards Control Organization (CDSCO) released an alert on 21st Jan 2015 informing state and local bodies that Roche’s blockbuster drug Avastin has not been accepted to treat any ophthalmology problems and can result in vision loss.

The notice comes 48 hours after authorities in two Indian states put sales of Avastin on hold.

As reported by Reuters, H.G….

Roche initiates its first clinical trial for Down Syndrome

BASEL, Switzerland and NUTLEY, NJ: Roche has announced the commencement of its first Phase 1 clinical trial to evaluate the safety and tolerability of a drug candidate that has been developed to treat cognitive and behavioral discrepancies related to Down syndrome.

Global Head of Roche Neurosciences Disease Translational Area, Luca Santarelli commented, “There is currently a large unmet medical need for the treatment…

US FDA approves Vemurafenib , a Melanoma Drug

The United States Food and Drug Administration has approved vemurafenib (Zelboraf), a drug designed to treat patients with metastatic melanoma. Vemurafenib is a BRAF-inhibitor and is a personalized investigational drug intended to treat patients who test positive for the BRAF mutation. It acts by particularly restricting the mutant BRAF-protein activity seen in nearly 50% of melanoma cases (the most aggressive and fatal…

Roche’s melanoma treatment drug Zelboraf receives FDA Approval

WASHINGTON (AP) — The United States Food and Drug Administration has approved the first and one-of-a-kind drug manufactured by Roche that is intended to combat the worst form of skin cancer.

The drug Zelboraf is the first treatment for melanoma and targets a specific gene mutation occuring in nearly 50% of patients with skin-cancer tumors. The agency also declared that it provided…

FDA approval of Regeneron’s Eylea delayed by 3 months

TARRYTOWN, N.Y. (AP) — Earlier on Tuesday, Regeneron Pharmaceuticals Inc. announced that FDA review of the company’s experimental eye drug, Eylea, has been postponed by 3 months from the anticipated date, and the agency is expected to complete drug review by Nov 18.

In aftermarket trading, Regeneron shares slipped over 7 percent.

The drug has been developed for the treatment of “wet” age-related macular…

Roche, Daiichi expect early FDA approval for Melanoma Drug Vemurafenib

Information gathered from close sources reveal that the US regulatory agency might approve an oral BRAF inhibitor vemurafenib jointly developed by Roche and its partner Daiichi Sankyo for treating certain patients with metastatic melanoma, no later than this week. While Roche filed for drug clearance May, the FDA was expected to pass a judgment on the application by November.

Although the source stated,…

Roche returned the financial aid offered to keep the Florence plant open

FLORENCE, S.C. (AP) — Roche has returned to the state the financial aid offered to keep the company’s Florence plant open, said Hugh Leatherman, the Senator of South Carolina.

In an attempt to persuade Roche Carolina to keep its unit open, Leatherman made efforts to raise $500,000 in incentive money from the state Commerce Department, reported the Morning News of Florence. Earlier in November,…